Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Share-based Compensation: 2020-2023

Historic Share-based Compensation for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to $939,000.

  • Candel Therapeutics' Share-based Compensation rose 48.11% to $939,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.1 million, marking a year-over-year increase of 33.98%. This contributed to the annual value of $5.3 million for FY2024, which is 71.85% up from last year.
  • Latest data reveals that Candel Therapeutics reported Share-based Compensation of $939,000 as of Q4 2023, which was up 36.88% from $686,000 recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Share-based Compensation ranged from a high of $1.9 million in Q3 2021 and a low of -$446,000 during Q4 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $709,500 (2023), whereas its average is $696,750.
  • Examining YoY changes over the last 5 years, Candel Therapeutics' Share-based Compensation showed a top increase of 3,440.62% in 2021 and a maximum decrease of 125.44% in 2021.
  • Candel Therapeutics' Share-based Compensation (Quarterly) stood at $1.8 million in 2020, then plummeted by 125.44% to -$446,000 in 2021, then skyrocketed by 242.15% to $634,000 in 2022, then soared by 48.11% to $939,000 in 2023.
  • Its last three reported values are $939,000 in Q4 2023, $686,000 for Q3 2023, and $733,000 during Q2 2023.